Vector starts clinical trials of coronavirus vaccine - Rospotrebnadzor head Popova
MOSCOW. July 28 (Interfax) - The state research center Vector under the Russian Federal Service for Health and Consumer Rights (Rospotrebnadzor) has started clinical trials of a coronavirus vaccine it has developed, Rospotrebnadzor head Anna Popova said.
"We've received clearance to conduct clinical studies of the coronavirus vaccine the other day. We started phases 1 and 2 of its clinical trials yesterday, on the 27th [of July]," Popova said during an online symposium on Tuesday.
As reported earlier, Vector received clearance to start clinical studies of the vaccine on July 24.
Earlier reports said that the Sechenov First Moscow State Medical University and the Burdenko Military Clinical Hospital on July 20 discharged two second groups of volunteers on whom a coronavirus vaccine developed by the Gamaleya Research Center was tested. These studies have now to be reviewed and their findings passed to the Health Ministry, which is supposed to make a decision on starting the vaccine's application.
After the vaccine's registration, the third phase of its trials will begin, during which those vaccinated will be monitored for possible side effects.